Deadly Collision Claims 67 Lives in U.S. Air Disaster | At Least 30 Dead and Many Injured in Stampede at Maha Kumbh Mela in India | Cambodia to Host 2025 National Chapei Dang Veng Festival from June 11-13 | Senate President Hun Sen Reflects on Cambodia’s Development and ASEAN Integration | ASEAN Secretary-General Hails Samdech Techo Hun Sen's Vision at Policy Speech | Cambodia Temporarily Bans Livestock and Meat Imports from Thailand Amid Anthrax Outbreak |
Deadly Collision Claims 67 Lives in U.S. Air Disaster | At Least 30 Dead and Many Injured in Stampede at Maha Kumbh Mela in India | Cambodia to Host 2025 National Chapei Dang Veng Festival from June 11-13 | Senate President Hun Sen Reflects on Cambodia’s Development and ASEAN Integration | ASEAN Secretary-General Hails Samdech Techo Hun Sen's Vision at Policy Speech | Cambodia Temporarily Bans Livestock and Meat Imports from Thailand Amid Anthrax Outbreak |

EU Drug Regulator Approves Pfizer Covids Pill for High-Risk Patients

  • Posted Jan 28, 2022 11:02 by Rosahlee Bautista
  • 2195
  Aa |   aA

INTERNATIONAL: The European Union's drug regulator on Thursday , January 2, has given the green light to Pfizer’s antiviral Covid-19 pill for treating adults at risk of severe illness, as the region scrambles to boost its arsenal to fight the Omicron variant.

The endorsement by the European Medicines Agency for a conditional approval, if followed as usual by the European Commission, allows European Union member states to deploy the drug after the regulator gave guidance for its emergency use late last year.

Italy, Germany and Belgium are among a handful of European Union countries that have bought the drug, branded as Paxlovid.

The United States in December has authorised Paxlovid and Merck's similar drug molnupiravir.

These oral drugs, especially Pfizer's, are seen as promising new treatment options that can be taken at home at the onset of Covid-19 symptoms to help prevent hospitalisations and deaths.

Paxlovid, a two-drug antiviral regimen, was nearly 90 percent effective in preventing hospitalisations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retained its effectiveness against the Omicron variant as well.


Related News